Autres langues Acumen Pharmaceuticals, Inc.

Actions

ABOS

US00509G2093

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 20/05/2024			Varia. 5j.	Varia. 1 janv.
3,84 ^USD	+5,21 %		+14,29 %	0,00 %

15/05	Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM
14/05	Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights	14/05
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference	08/05
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	08/05
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease	08/05
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	08/05
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024	07/05
AAN 2024 Poster - INTERCEPT-AD, a Phase 1 Study of Sabirnetug (ACU193): Safety, Target Engagement, and Biomarker Changes	02/05
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting	17/04
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting	16/04
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04/04
Borsa svizzera chiude in rialzo, SMI +0,64%	04/04
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04/04
Lonza produziert Arzneimittelkandidaten von Acumen Pharmaceuticals	04/04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease	04/04
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04/04
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	27/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights	26/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Acumen Pharmaceuticals, Inc.

Actions

ABOS

US00509G2093

Autres langues

Filtres